Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Target Oncol
.
2023 Mar;18(2):311.
doi: 10.1007/s11523-023-00947-9.
Authors
Sanjay Popat
1
2
,
Myung-Ju Ahn
3
,
Simon Ekman
4
5
,
Natasha B Leighl
6
,
Suresh S Ramalingam
7
,
Thanyanan Reungwetwattana
8
,
Shankar Siva
9
10
,
Masahiro Tsuboi
11
,
Yi-Long Wu
12
,
James Chih-Hsin Yang
13
Affiliations
1
Lung Unit, Royal Marsden Hospital, London, UK. sanjay.popat@rmh.nhs.uk.
2
Division of Clinical Studies, Institute of Cancer Research, London, UK. sanjay.popat@rmh.nhs.uk.
3
Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
4
Theme Cancer, Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden.
5
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
6
Medical Oncology, Princess Margaret Cancer Center, Toronto, Canada.
7
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
8
Division of Medical Oncology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
9
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
10
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
11
Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
12
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
13
Department of Oncology, National Taiwan University Hospital Cancer Center, Taipei, Taiwan.
PMID:
36752975
DOI:
10.1007/s11523-023-00947-9
No abstract available
Publication types
Published Erratum